CLINUVEL Kommuniqué III
Sehr geehrte Aktionärinnen und Aktionäre, liebeFreunde, EINFÜHRUNG Während des Lockdown hatte unser...
Read More
Media Release - First stroke patient treated with afamelanotide
Melbourne, Australia, 07 June 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
First stroke patient treated with afamelanotide
Melbourne, Australia, 07 June 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Communiqué III
Dear shareholders, friends, INTRODUCTION During the lockdowns our team has had plenty...
Read More
Appendix 3Y Change of Director's Interest Notice
Information or documents not available now must be given to ASX as...
Read More
SCIENTIFIC COMMUNIQUÉ X: Photoprotection and the significance of Minimal Erythema Dose (MED) testing
May 2021 ABSTRACT The sun continuously emits radiant energy across the solar...
Read More
Appendix 4C & Activity Report
Melbourne, Australia, 29 April 2021 CLINUVEL PHARMACEUTICALS LTD today announced its Appendix...
Read More
CLINUVEL Strategic Update II
Melbourne, Australia, 12 April 2021 CLINUVEL today announced its second Strategic Update,...
Read More
CLINUVEL Kommuniqué II
Liebe Aktionäre, Freunde Wir begrüßen viele neue Aktionäre, insbesondere die große Anzahl...
Read More
CLINUVEL Communiqué II
Dear shareholders, friends We welcome many new shareholders, especially the large number...
Read More
Chair's Letter I
Direction and horizon In the last weeks, I have had investor questions...
Read More
Media Release - CLINUVEL Expands DNA Repair Program
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...
Read More
SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)
CLINUVEL today announced that it has reached agreement with clinical and academic...
Read More
Investor Presentation - Daiwa Investment Conference Tokyo 2021
10 March 2021 – Melbourne, Australia On 10 March 2021 CLINUVEL presented...
Read More